← Leaderboards
Jonathan P. Butchar
Ohio State University
$1,489,934
Attributed
$2,979,868
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $621.6K · FY2017–25$1M$750K$500K$250K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,979,868 · 2
By mechanism
R01$2,979,868 · 2
Top collaborators
- Susheela Tridandapani7 shared
Most similar at Ohio State University
Same institution · by research overlap
- Susheela Tridandapani$6,556,394
- Jennifer A. Woyach$6,733,332
- Michael A Caligiuri$65,062,344
- Lapo Alinari$4,506,413
- William E. Carson$27,905,247
Others in their field
Other Emerging Leaders on “Monoclonal Antibodies”
- Bambra Strokes · Ppd Development Lp$461,655,950
- Yunda Huang · Fred Hutchinson Cancer Center$72,724,451
- Wendy Sammons-Jackson · National Institute Of Allergy And Infectious Diseases$27,369,420
- Arnab Kumar Chatterjee · Washington University$22,541,385
- Julie Ake · National Institute Of Allergy And Infectious Diseases$22,000,000
- Timothy Fouts · Advanced Bioscience Laboratories, Inc.$20,284,295
Research focus
Monoclonal AntibodiesNeoplastic CellLigandsMolecularMyeloid CellsNatural Killer CellsExperimental StudyImmuneMacrophageMediatingMonocyteMouse ModelBloodB-LymphocytesAntibody TherapyCytotoxicCancer TherapyAntibodiesCytokineCellsChronic Lymphocytic LeukemiaClinical TrialsCytotoxicityNurses
Grant awards (7)
Novel enhancement of antibody therapy through NOD2 activation$614,578
R01 · FY2025 · CA
Novel enhancement of antibody therapy through NOD2 activation$621,637
R01 · FY2024 · CA
Myeloid cell-derived Granzyme B as an inducible enhancer of cancer immunotherapy$352,513
R01 · FY2021 · CA
Myeloid cell-derived Granzyme B as an inducible enhancer of cancer immunotherapy$351,988
R01 · FY2020 · CA
Myeloid cell-derived Granzyme B as an inducible enhancer of cancer immunotherapy$340,933
R01 · FY2019 · CA
Myeloid cell-derived Granzyme B as an inducible enhancer of cancer immunotherapy$350,436
R01 · FY2018 · CA
Myeloid cell-derived Granzyme B as an inducible enhancer of cancer immunotherapy$347,783
R01 · FY2017 · CA